Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, helped along by a shiny sun enveloping the otherwise chilly Pharmalot campus. A few cups of stimulation can also be useful, we are the first to confess. Meanwhile, we are as busy as ever, foraging for interesting items. On that note, here are a few tidbits to help you on your own journey. We hope all goes well today and that you conquer the world. And as always, do keep in touch. We appreciate your insights …

A Food and Drug Administration advisory panel overwhelmingly voted to approve an Amgen (AMGN) osteoporosis treatment for postmenopausal women at high risk for fracture, Reuters reports. The panel voted 16-1 in favor of the monthly injection developed jointly with UCB. The drug, Evenity, helps reduce the risk of fracture by increasing bone formation and inhibiting breakdown of bone minerals. However, the panel raised concerns about cardiovascular safety risks linked to the drug, which FDA staff reviewers had cited as the main reason for convening the panel meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!